Skip to main content

Newsroom press releases

31/07/26 - 12:50

Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
Financial Data

20/05/26 - 11:16

Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
Financial Data

08/05/26 - 17:54

Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
Financial Data

20/03/26 - 17:44

Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
Financial Data

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
Financial Data

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
Financial Data

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
Financial Data

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
Financial Data